Sex: M
Vaccine: COVID19
Symptoms: Incontinence, Joint stiffness, Lumbar spinal stenosis, Mobility decreased, Muscle tightness
Clinical narrative: STENOSIS IN L1 AND L2; EXPERIENCED INCONTINENCE ISSUES; something pressing on a nerve; TIGHTNESS IN HIPS AND LOWER BACK/FELT SOMETHING PRESSING ON A NERVE; TIGHTNESS IN HIPS AND LOWER BACK; Mobility Issue; This spontaneous case was reported by a consumer and describes the occurrence of LUMBAR SPINAL STENOSIS (STENOSIS IN L1 AND L2), INCONTINENCE (EXPERIENCED INCONTINENCE ISSUES), SENSORY DISTURBANCE (something pressing on a nerve), MUSCLE TIGHTNESS (TIGHTNESS IN HIPS AND LOWER BACK/FELT SOMETHING PRESSING ON A NERVE) and JOINT STIFFNESS (TIGHTNESS IN HIPS AND LOWER BACK) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    The patient's past medical history included Hip replacement and Fusion lumbar spine (FUSION WAS DONE ON L3, L5).   In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose., UPADACITINIB (RINVOQ) (Oral) dosage was changed to at an unspecified dose and UPADACITINIB (RINVOQ) (Oral) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced LUMBAR SPINAL STENOSIS (STENOSIS IN L1 AND L2), INCONTINENCE (EXPERIENCED INCONTINENCE ISSUES), SENSORY DISTURBANCE (something pressing on a nerve), MUSCLE TIGHTNESS (TIGHTNESS IN HIPS AND LOWER BACK/FELT SOMETHING PRESSING ON A NERVE), JOINT STIFFNESS (TIGHTNESS IN HIPS AND LOWER BACK) and MOBILITY DECREASED (Mobility Issue). At the time of the report, LUMBAR SPINAL STENOSIS (STENOSIS IN L1 AND L2), INCONTINENCE (EXPERIENCED INCONTINENCE ISSUES) and SENSORY DISTURBANCE (something pressing on a nerve) had not resolved and MUSCLE TIGHTNESS (TIGHTNESS IN HIPS AND LOWER BACK/FELT SOMETHING PRESSING ON A NERVE), JOINT STIFFNESS (TIGHTNESS IN HIPS AND LOWER BACK) and MOBILITY DECREASED (Mobility Issue) had resolved.            Concomitant product use was not provided by the reporter.  The patient had received dose 1, dose 2 and dose 3 (booster dose) of the Moderna covid-19 vaccines respectively. The patient had hip replacement before starting Rinvoq. A fusion had done on L3, L5 before starting Rinvoq. He had experienced a tightness in his hips and lower back for the past few months as of 19-Jan-2022. His physician informed that there was a stenosis in L1 and L2. It felt as if there was something pressing on a nerve and had experienced incontinence issues. When he took his two COVID vaccinations he stopped taking Rinvoq a week before and a week after. Both the times took some time before he noticed relief from tightness and overall mobility issue, a bit longer after the second vaccination to regain his mobility. This was the only adverse event associated with the covid vaccination. On unknown dates, mobility issue and tightness in hips and lower back resolved.  No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact